Veracyte Q3: Beats Expectations, Projects Growth
Update: 2025-11-04
Description
Veracyte, a molecular diagnostic company, reported a net income of $19.1 million, or $0.24 per share, for Q3. This surpassed analysts' expectations of $0.32 per share. The company also generated $131.9 million in revenue, exceeding the projected $125 million. Veracyte's strong performance and consistent outperformance suggest a robust business model and growing demand for its services. The company projects full-year revenue between $506 million and $510 million, indicating confidence in its growth trajectory.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
